Skip to main content
OTCMKTS:BNKL

Bionik Laboratories Stock Forecast, Price & News

$1.36
-0.07 (-4.90 %)
(As of 05/13/2021 10:10 PM ET)
Add
Compare
Today's Range
$1.26
$1.36
50-Day Range
$1.36
$3.00
52-Week Range
$0.75
$4.50
Volume1,200 shs
Average Volume646 shs
Market Capitalization$6.81 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.3
30 days | 90 days | 365 days | Advanced Chart
Receive BNKL News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionik Laboratories and its competitors with MarketBeat's FREE daily newsletter.


Bionik Laboratories logo

About Bionik Laboratories

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion ARM that allows clinicians to deliver sensor motor therapy to the shoulder and elbow to develop new neural pathways; InMotion ARM/HAND for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion WRIST, a rehabilitation device that enables clinicians to deliver optimum intensive sensor motor wrist and forearm therapy to patients with neurological conditions. The company also engages in developing InMotion HOME, an upper extremity product that allows patients to extend their therapy for as long as needed while rehabilitating at home; ARKE, a robotic lower body exoskeleton designed for wheelchair bound individuals suffering from spinal cord injuries, strokes, and other mobility disabilities; and InMotion Connect, a solution to meet the data connectivity and analytics needs of hospitals and healthcare facilities. Bionik Laboratories Corp. was founded in 2010 and is headquartered in Toronto, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BNKL
CUSIPN/A
CIKN/A
Phone416-640-7887
Employees18
Year FoundedN/A

Sales & Book Value

Annual Sales$2.15 million
Book Value$2.67 per share

Profitability

Net Income$-25,020,000.00
Net Margins-1,419.25%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$6.81 million
Next Earnings Date6/29/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.79 out of 5 stars

Medical Sector

1219th out of 2,042 stocks

Surgical Appliances & Supplies Industry

30th out of 40 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bionik Laboratories (OTCMKTS:BNKL) Frequently Asked Questions

What stocks does MarketBeat like better than Bionik Laboratories?

Wall Street analysts have given Bionik Laboratories a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bionik Laboratories wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bionik Laboratories' next earnings date?

Bionik Laboratories is scheduled to release its next quarterly earnings announcement on Tuesday, June 29th 2021.
View our earnings forecast for Bionik Laboratories
.

How has Bionik Laboratories' stock price been impacted by COVID-19 (Coronavirus)?

Bionik Laboratories' stock was trading at $1.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BNKL shares have decreased by 22.3% and is now trading at $1.36.
View which stocks have been most impacted by COVID-19
.

Who are Bionik Laboratories' key executives?

Bionik Laboratories' management team includes the following people:
  • Dr. Eric Michel Dusseux M.D., MSc, MBA, CEO & Director (Age 53, Pay $639.3k)
  • Mr. Michal Prywata, Co-Founder & Director (Age 30, Pay $235.86k)
  • Mr. Loren W. Wass, Chief Commercial Officer (Age 59, Pay $250.39k)
  • Mr. Richard Paul Russo Jr., CPA, Chief Financial Officer (Age 41)

Who are some of Bionik Laboratories' key competitors?

What other stocks do shareholders of Bionik Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionik Laboratories investors own include Co-Diagnostics (CODX), iBio (IBIO), PerkinElmer (PKI), PharmaCyte Biotech (PMCB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), Ascent Solar Technologies (ASTI), BioRestorative Therapies (BRTX) and Digital Ally (DGLY).

What is Bionik Laboratories' stock symbol?

Bionik Laboratories trades on the OTCMKTS under the ticker symbol "BNKL."

How do I buy shares of Bionik Laboratories?

Shares of BNKL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bionik Laboratories' stock price today?

One share of BNKL stock can currently be purchased for approximately $1.36.

How much money does Bionik Laboratories make?

Bionik Laboratories has a market capitalization of $6.81 million and generates $2.15 million in revenue each year.

How many employees does Bionik Laboratories have?

Bionik Laboratories employs 18 workers across the globe.

What is Bionik Laboratories' official website?

The official website for Bionik Laboratories is www.bioniklabs.com.

Where are Bionik Laboratories' headquarters?

Bionik Laboratories is headquartered at 483 Bay Street N105, Toronto A6, M5G2C9.

How can I contact Bionik Laboratories?

Bionik Laboratories' mailing address is 483 Bay Street N105, Toronto A6, M5G2C9. The company can be reached via phone at 416-640-7887 or via email at [email protected]


This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.